Travere Therapeutics (TVTX) SVP sells 2,910 shares in Rule 10b5-1 trade

Rhea-AI Filing Summary

Travere Therapeutics, Inc. reported an insider stock sale by its SVP and Chief Accounting Officer. On 12/15/2025, the executive sold 2,910 shares of Travere common stock at $36 per share, according to a Form 4 insider trading report.

After this transaction, the officer beneficially owns 45,635 shares directly. The filing notes that the sale was made under a written trading plan adopted on June 10, 2025 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

Insider Trade Summary

Net Seller: 2,910 shares

Net Sell 1 txn

Insider Calvin Sandra

Role SVP, CHIEF ACCOUNTING OFFICER

Sold 2,910 shs ($105K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,910	$36.00	$105K

Holdings After Transaction: Common Stock — 45,635 shares (Direct)

Footnotes (1)

1. F1. This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/16/2025 - 04:23 PM Learn about SEC filing dates

FAQ

What insider transaction did Travere Therapeutics (TVTX) report in this filing?

The filing reports that a Travere Therapeutics executive sold 2,910 shares of common stock on 12/15/2025 at a price of $36 per share.

Who executed the stock sale reported by Travere Therapeutics (TVTX)?

The transaction was made by a company officer who serves as SVP, Chief Accounting Officer of Travere Therapeutics, Inc.

How many Travere Therapeutics (TVTX) shares does the insider own after the sale?

Following the reported sale, the officer beneficially owns 45,635 shares of Travere Therapeutics common stock in direct ownership.

When did the Travere Therapeutics (TVTX) insider transaction take place?

The reported sale of Travere Therapeutics common stock occurred on December 15, 2025, as shown in the insider transaction table.

Was the Travere Therapeutics (TVTX) insider sale under a Rule 10b5-1 trading plan?

Yes. The explanation states that the sale was made under a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c).

Is the Travere Therapeutics (TVTX) Form 4 filed by one or multiple reporting persons?

The document indicates that it is a Form filed by one reporting person, not a joint or group filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Calvin Sandra

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		S(1)		2,910	D	$36	45,635	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.